| Protein Name | TAR DNA-binding protein 43 |
|---|
| Gene | TARDBP |
|---|
| UniProt | Q13148 |
|---|
| PDB Structures | 2N4P, 2N4O, 3D2W |
|---|
| Molecular Weight | 44.7 kDa (414 aa) |
|---|
| Subcellular Localization | Nuclear (cytoplasmic in disease) |
|---|
| Protein Family | Heterogeneous nuclear ribonucleoprotein (hnRNP) family |
|---|
| Diseases | ALS, FTD, LATE |
|---|
Tdp 43 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TDP-43 (TAR DNA-binding protein 43) is an RNA/DNA-binding protein encoded by the TARDBP gene on chromosome 1p36.22. Originally identified as a transcriptional repressor that binds to the transactive response (TAR) element of HIV-1, TDP-43 has emerged as a central player in neurodegenerative disease[1]. Pathological aggregation of TDP-43 in the cytoplasm is the hallmark of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD-TDP), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Remarkably, TDP-43 pathology is present in over 95% of ALS cases and approximately 50% of FTD cases, making it one of the most common proteinopathies in human neurodegeneration. The identification of disease-causing mutations in TARDBP established TDP-43 as a direct pathogenic driver rather than a bystander[2].
¶ Domain Organization
TDP-43 contains several functionally distinct domains:
- N-terminal domain (1-102 aa): Contains the nuclear localization signal (NLS, residues 82-98) and mediates protein-protein interactions
- RNA recognition motif 1 (RRM1, 106-176 aa): Binds UG-rich RNA sequences with high affinity
- RNA recognition motif 2 (RRM2, 191-259 aa): Provides additional RNA-binding capacity
- C-terminal glycine-rich domain (274-414 aa): Low-complexity prion-like region that mediates aggregation
The C-terminal domain is particularly important for disease pathogenesis, as nearly all pathogenic mutations cluster in this region[3].
The C-terminal low-complexity domain exhibits:
- Prion-like properties (can form amyloid fibrils)
- Liquid-liquid phase separation (LLPS) capability
- Stress granule recruitment under cellular stress
- Conformational flexibility enabling multiple protein interactions
TDP-43 is a multifunctional RNA-binding protein involved in:
- Alternative splicing: Regulates inclusion/exclusion of specific exons in pre-mRNAs
- mRNA stability: Binds and stabilizes target mRNAs
- RNA transport: Participates in mRNA trafficking to neuronal dendrites
- Transcriptional regulation: Acts as both activator and repressor
- miRNA processing: Involved in microRNA biogenesis
Over 6,000 RNA targets have been identified through CLIP-seq studies, demonstrating the extensive regulatory network of TDP-43.
Under cellular stress (oxidative stress, heat shock, osmotic stress), TDP-43:
- Relocalizes to stress granules (mRNA-protein aggregates)
- Temporarily halts translation
- Protects mRNA integrity
- Facilitates stress recovery
TDP-43 constantly shuttles between the nucleus and cytoplasm:
- Nuclear import via importin-α/β through the NLS
- Nuclear export via CRM1/exportin1
- Balance disrupted in disease
TDP-43 pathology in ALS is characterized by:
- Cytoplasmic inclusions: Hyperphosphorylated, ubiquitinated TDP-43 aggregates
- Nuclear clearance: Loss of nuclear TDP-43 in affected neurons
- Spliceopathy: Aberrant RNA processing due to TDP-43 dysfunction
- Mitochondrial dysfunction: Impaired energy metabolism
- Axonal transport defects: Disrupted mRNA trafficking
- Neuroinflammation: Activated microglia surrounding inclusions
Over 50 pathogenic mutations in TARDBP have been identified, primarily in the C-terminal domain. These mutations increase aggregation propensity and alter RNA binding.
Frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) is classified into subtypes:
- Type A: Neuronal intranuclear inclusions, associated with GRN mutations
- Type B: Moderate neuronal cytoplasmic inclusions, associated with C9orf72
- Type C: Prominent dendritic inclusions, associated with sporadic cases
Limbic-predominant age-related TDP-43 encephalopathy is characterized by:
- TDP-43 pathology primarily in limbic regions
- Amnestic dementia phenotype
- Overlap with Alzheimer's disease pathology
- Loss of nuclear function: Reduced RNA processing capacity
- Gain of toxic function: Sequestration of normal TDP-43 and other proteins
- Stress granule persistence: Abnormal stress granule dynamics
- Mitochondrial dysfunction: Imported mitochondrial proteins affected
| Mutation |
Domain |
Effect |
Disease |
| A315T |
C-terminal |
Increased aggregation |
ALS/FTD |
| G348C |
C-terminal |
Altered RNA binding |
ALS |
| Q331K |
C-terminal |
Reduced splicing |
ALS |
| M337V |
C-terminal |
Enhanced aggregation |
ALS/FTD |
| A382T |
C-terminal |
Pathogenic |
ALS |
| N390D |
C-terminal |
Altered localization |
FTD |
| G294A |
C-terminal |
Enhanced aggregation |
ALS |
- Antisense oligonucleotides (ASOs): Reduce mutant TDP-43 expression
- AAV-delivered shRNAs: Knockdown of pathogenic TDP-43
- CRISPR editing: Correct mutations or modulate expression
- Aggregation inhibitors: Prevent or reverse TDP-43 aggregation
- Kinase inhibitors: Target phosphorylation pathways
- Nuclear import modulators: Restore nuclear localization
- Mitochondrial protectors: Counteract energy deficits
- RNA splicing modulators: Correct spliceopathy
- Anti-inflammatory agents: Reduce neuroinflammation
- TDP-43 in cerebrospinal fluid (CSF)
- Phosphorylated TDP-43 in blood
- Imaging markers for cortical thinning
¶ Drug Candidates in Development
| Drug/Approach |
Mechanism |
Stage |
Status |
| ASOs targeting TDP-43 |
Gene silencing |
Preclinical |
Proof-of-concept |
| Small molecule aggregators |
Aggregation inhibition |
Discovery |
Lead optimization |
| AAV-shRNA delivery |
Knockdown therapy |
Discovery |
In development |
| Nuclear export inhibitors |
Restore localization |
Discovery |
Theoretical |
| Stress granule modulators |
Granule dynamics |
Discovery |
Early stage |
The study of Tdp 43 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neumann M, et al. (2006). "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS". Science 314(5796):130-133. PMID:16400152
- Sreedharan J, et al. (2008). "TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis". Science 319(5870):1668-1672. PMID:18801997
- Buratti E, et al. (2001). "Nuclear factor TDP-43 and SR proteins modulate alternative splicing of CFTR exon 9". Nucleic Acids Res 29(2):442-453. PMID:11266564
- Arai T, et al. (2006). "TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis". Biochem Biophys Res Commun 351(3):602-611. PMID:17097676
- Lagier-Tourenne C, et al. (2010). "TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia". Lancet Neurol 9(10):995-1007. PMID:20865438
- Johnson BS, et al. (2009). "TDP-43: an emerging therapeutic target in neurodegenerative disease". Nat Rev Drug Discov 8(12):945-954. PMID:19214184
- King NE, et al. (2012). "Therapeutic targeting of TDP-43 and FUS". Neurobiol Dis 48(2):219-227. PMID:22030453
- Liu Y, et al. (2021). "TDP-43 in Alzheimer's disease and related disorders". Acta Neuropathol 142(3):395-411. PMID:33988831